Livmarli patent litigations?

A quick note: Livmarli is the brand name for maralixibat, an IBAT inhibitor used for certain cholestatic liver diseases (notably PFIC). Patent disputes around it would typically involve composition-of-matter patents for maralixibat, method-of-use claims (e.g., treating PFIC), and related formulation/process patents, plus any licensing or exclusivity issues.

If you want, I can help with up-to-date, docketed information. To proceed I need a bit more from you:
- Do you want ongoing litigation details, or historical cases?
- Which jurisdictions are of interest (US, EU, UK, others)?
- Do you want a brief overview or full case-by-case summaries (case numbers, courts, current status)?

If you’d like me to fetch current public information, I can look up:
- Patent families around maralixibat (USPTO, EPO, Google Patents)
- Any court filings or press releases from Mirum Pharmaceuticals or licensees
- News or docket entries for specific cases (if they exist)

Tell me your preferences (scope and timeframe), and I’ll tailor the answer with the latest available details.